Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single‐centre experience
- 12 February 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5), 939-940
- https://doi.org/10.1111/ced.14611
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease (1), commonly related to other atopic manifestations such as food allergy, rhinitis, asthma and conjunctivitis. (2). More than one third of AD patients (31% ‐56%) develop an episode of conjunctivitis in their lifetime, usually related to the severity of dermatitis (3).Keywords
This publication has 8 references indexed in Scilit:
- Atopic dermatitisThe Lancet, 2020
- Mechanisms of DupilumabClinical & Experimental Allergy, 2019
- Conjunctivitis in dupilumab clinical trialsBritish Journal of Dermatology, 2019
- Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic DermatitisJAMA Dermatology, 2018
- Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)Journal of the American Academy of Dermatology, 2018
- Diagnosis and Management of Conjunctivitis for the DermatologistJournal of Cutaneous Medicine and Surgery, 2017
- Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitisJournal of the American Academy of Dermatology, 2017
- Prevalence of Atopic Dermatitis in Italian Schoolchildren: Factors Affecting its VariationActa Dermato-Venereologica, 2008